Prestige Consumer Healthcare (PBH) Total Current Liabilities (2011 - 2026)
Prestige Consumer Healthcare (PBH) posted quarterly Total Current Liabilities of $139.6 million for Q4 2025, up 36.09% year-over-year from $102.5 million in Q4 2024, and up 3.68% quarter-over-quarter from $134.6 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Total Current Liabilities (2011 - 2026) Analysis & Trends
Prestige Consumer Healthcare's Total Current Liabilities history runs 15 years deep, the most recent figure standing at $139.6 million for Q4 2025.
- In Q4 2025, Total Current Liabilities rose 36.09% year-over-year to $139.6 million; the TTM figure through Dec 2025 stood at $139.6 million (up 36.09% YoY), while the FY2025 annual figure was $106.6 million, down 8.91% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $139.6 million, up from $134.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $160.7 million in Q1 2023, with the low at $102.5 million in Q4 2024.
- The 5-year median for Total Current Liabilities is $132.2 million (2023), against an average of $131.9 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities decreased 27.17% in 2024, then surged 36.09% in 2025.
- Prestige Consumer Healthcare's Total Current Liabilities stood at $135.1 million in 2021, then grew by 18.54% to $160.2 million in 2022, then fell by 20.44% to $127.4 million in 2023, then declined by 19.53% to $102.5 million in 2024, then soared by 36.09% to $139.6 million in 2025.
- Business Quant data shows PBH's Total Current Liabilities at $139.6 million in Q4 2025, $134.6 million in Q3 2025, and $109.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 1.79 Bn |
| 10 | Prestige Consumer Healthcare | 2.44 Bn | 2.38 Bn | - | 120.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 120.92 Mn |
| Dec 31, 2025 | 139.56 Mn |
| Sep 30, 2025 | 134.60 Mn |
| Jun 30, 2025 | 109.67 Mn |
| Mar 31, 2025 | 106.62 Mn |
| Dec 31, 2024 | 102.55 Mn |
| Sep 30, 2024 | 106.91 Mn |
| Jun 30, 2024 | 114.12 Mn |
| Mar 31, 2024 | 117.05 Mn |
| Dec 31, 2023 | 127.44 Mn |
| Sep 30, 2023 | 129.70 Mn |
| Jun 30, 2023 | 147.27 Mn |
| Mar 31, 2023 | 160.72 Mn |
| Dec 31, 2022 | 160.18 Mn |
| Sep 30, 2022 | 152.31 Mn |
| Jun 30, 2022 | 155.35 Mn |
| Mar 31, 2022 | 143.42 Mn |
| Dec 31, 2021 | 135.13 Mn |
| Sep 30, 2021 | 148.94 Mn |
| Jun 30, 2021 | 125.05 Mn |